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Parkinson’s disease (PD) is typically well recognized by its characteristic motor symptoms (e.g., bradykinesia, rigidity, and
tremor). /e cognitive symptoms of PD are increasingly being acknowledged by clinicians and researchers alike. However, PD
also involves a host of emotional and communicative changes which can cause major disruptions to social functioning. /ese
incude problems producing emotional facial expressions (i.e., facial masking) and emotional speech (i.e., dysarthria), as well as
difficulties recognizing the verbal and nonverbal emotional cues of others. /ese social symptoms of PD can result in severe
negative social consequences, including stigma, dehumanization, and loneliness, which might affect quality of life to an even
greater extent than more well-recognized motor or cognitive symptoms. It is, therefore, imperative that researchers and clinicans
become aware of these potential social symptoms and their negative effects, in order to properly investigate and manage the
socioemotional aspects of PD. /is narrative review provides an examination of the current research surrounding some of the
most common social symptoms of PD and their related social consequences and argues that proactively and adequately addressing
these issues might improve disease outcomes.
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative movement
disorder characterized by hallmark motor symptoms (e.g.,
tremor, bradykinesia, and rigidity [1]) brought about by
progressive loss of dopaminergic neurons in the substantia
nigra pars compacta [2, 3]. PD is currently estimated to affect
upwards of 6 million individuals worldwide [4], with
prevalence rates expected to double in the coming years
[5, 6]. /ere is currently no cure for PD, though motor
symptoms are often well controlled by dopaminergic
therapies such as levodopa (i.e., dopamine precursor) and
dopamine agonists. Unfortunately, these medications re-
quire higher dosages over time to achieve the same level of
control over motor symptoms [7].
In addition to the hallmark motor symptoms of PD,
researchers have come to appreciate cognitive symptoms
that also affect PD patients. /ese include disruptions to
executive processes such as learning and decision making,
which are differentially impacted by dopaminergic therapies
[8]. For example, compared to PD patients tested OFF
medication, PD patients ON medication are better at
selecting previously learned responses, but have a harder
time learning stimulus-response associations in the first
place [9, 10]. Similarly, dopaminergic medication appears to
improve deficits in task switching in PD patients, but
worsens performance on probabilistic reversal learning tasks
[11]. Ongoing research is still uncovering the complex na-
ture of cognitive symptoms of PD.
It has also become clear that PD involves a variety of
social symptoms, although these are not as well understood
as the motor or cognitive symptoms. In particular, PD
patients experience disruptions in emotional expression
[12, 13], recognizing others’ expressions [14], as well as
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emotional speech production [15] and perception [16, 17].
/ese social problems greatly impact patients and their
families and can ultimately reduce quality of life [18].
Although the broad nature of these topics prevents us
from conducting a systematic review, we hope to provide a
general overview of these interconnected areas by high-
lighting some pertinent experiments and synthesizing ideas
across studies. In this narrative review we, therefore, sum-
marize studies that examine the social communication
changes that can occur in PD, identify some of the negative
social consequences that can arise as a result, and argue that
greater awareness of these changes might help improve
disease management.
2. Social Communication Challenges in PD
2.1. Facial Masking. One of the most salient emotional
symptoms experienced by PD patients is the reduced ability
to spontaneously display emotional facial expressions. /is
symptom, often referred to as facial masking, is attributed to
bradykinesia of the muscles required for facial expressions.
Masking often occurs bilaterally, despite the fact that PD
typically manifests with worse motor symptoms on one side
of the body [19]. Importantly, PD patients with masking do
not undergo a decrease in their ability to experience emo-
tional feelings [20]. In other words, these patients are simply
unable to display their internally felt emotions via facial
expressions. Patients with PD have deemed this inability to
accurately express internal emotions as a factor that de-
creases social wellbeing [21].
In particular, PD patients tend to demonstrate fewer, and
less realistic, smiles than healthy controls [22]. Simons et al.
[23] demonstrated this quite dramatically by observing
reactions when participants were given a surprise gift at the
end of the study. Only 73% of PD patients smiled upon
receiving the gift compared to 84% of healthy controls, and a
much smaller proportion (36%) of PD patients produced a
genuine (i.e., Duchenne) smile. /e majority produced non-
Duchenne smiles, marked by an absence of wrinkling at the
corners of the eyes [24]. Duchenne smiles can elicit empathy
and feelings of pleasure from observers [25] and, thus, serve
a functional purpose. Losing the ability to produce Du-
chenne smiles in PD can, therefore, have negative social
consequences such as the appearance that a patient is cold
and withdrawn [22].
Deficits in the spontaneous expression of other emotions
have also been observed in PD patients. For example, using
video-based automatic scoring algorithms, Bandini et al.
[26] suggest that PD patients are especially impaired at
spontaneously imitating anger and disgust. However, the
patient group in the study did not have as much difficulty
voluntarily producing an angry emotional expression when
asked to do so by an experimenter. Interestingly, some
studies have shown that intentional emotional displays can
also be affected by facial masking. Generally, these results
suggest that the basic emotions (i.e., happiness, anger,
disgust, fear, sadness, and surprise) are all affected equally by
facial masking in PD [27, 28].
In addition to facial masking, PD patients are less able to
modulate their emotional expressions. In an experiment
where spontaneous facial expressions were elicited after
smelling pleasant and unpleasant odours, PD patients were
less able to produce a requested expression that was in-
congruent with the valence of the smelled odour [23].
Problems with cognitive flexibility could underly this phe-
nomenon, as PD patients have shown difficulties switching
from a salient, automatic response to a response that is less
habitual [29–32]. In social interactions, it can be very
beneficial to modulate certain facial expressions depending
on the context. For example, disguising one’s frustrations in
a work meeting with a smile could help maintain a positive
relationship with coworkers. For PD patients, difficulty
modulating facial expressions could cause friction in social
relationships which can lead to negative consequences such
as increased risk of depression [33].
2.2. Emotion Recognition Problems. Additionally, some PD
patients experience difficulty recognizing the emotional
expressions of others, a phenomenon which has been
widely documented and is controversial [14]. Research in
this area tends to offer inconsistent conclusions, with some
studies finding global emotion recognition problems
[34–36], some reporting emotion-specific recognition
problems [37–39], and others reporting no deficit at all
[40–42]. /ese differences are likely due to several factors,
including methodological differences (e.g., lack of con-
sistency in the type of emotion recognition test and/or
stimuli) and heterogeneity in PD patient samples (e.g.,
differences in disease severity and symptom profiles). More
research is needed to clarify the nature of potential deficits
in emotion recognition among PD patients.
Furthermore, there is limited evidence on whether do-
paminergic therapy has any effect on emotion recognition.
Only one study [43] tested PD patients ON and OFF their
prescribed medication. Using a forced-choice recognition
test with prototypical basic emotion photographs as stimuli
(i.e., the Ekman 60-Faces test [44]), the authors demon-
strated that PD patients were generally worse than controls
at recognizing emotions, particularly when tested in the OFF
state. Although limited, some evidence suggests that the
administration of levodopa in healthy participants decreases
amygdala activation during emotion perception and rec-
ognition, but this was not associated with measurable de-
creases in emotion recognition accuracy [45, 46]. Taken
together, these studies indicate that dopaminergic medica-
tion indeed affects emotion recognition abilities, and this
should be a considered by future studies of emotion rec-
ognition in PD.
Interestingly, there is some evidence that the problems
PD patients have in recognizing others’ emotions are related
to their own facial masking [14, 34, 47]. According to
embodied simulation theory, mimicking an expression
provides sensorimotor cues which act as feedback to the
brain to aid in emotion recognition [48, 49]. Studies with
healthy participants have shown that disrupting facial
mimicry can impair emotion recognition [50, 51]. For
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example, when facial mimicry is blocked, such as through
facial manipulations including chewing gum or biting a
pencil [51] or chemical interference such as botulinum toxin
[50, 52], emotion recognition accuracy tends to decrease. If
masking decreases PD patients’ ability to mimic the ex-
pression of others, this might directly affect their emotion
recognition abilities. Indeed, facial mimicry deficits have
also been demonstrated in PD [33, 53], although only one
study has linked this deficit to reduced emotion recognition
accuracy [34].
2.3. Dysarthria. Some PD patients also
experience disruptions to their normal speech patterns, such
as dysarthria. Dysarthria involves producing speech which is
grammatically and syntactically correct, but that is marked
by abnormal rhythm, harsh voice, inappropriate pauses, and
prosodic loss [54]. PD patients with prosodic loss have
monotonous, nonemotional speech [55, 56]. Interestingly,
dysarthria might only manifest during spontaneous speech,
as opposed to other communication methods such as
singing or reading [57]. /e effect of dopaminergic medi-
cation on dysarthria and prosodic loss in PD remains rel-
atively unclear. Generally, it appears that while
dopaminergic medication (i.e., levodopa) might improve
some aspects of speech (e.g., vowel articulation [58]), speech
intelligibility and prosody are rarely affected [58–61].
However, some researchers have found improvements in the
ON medication state [62, 63]. Nevertheless, these disrup-
tions in spontaneous speech have been identified as a dis-
tressing factor in the lives of patients [64] likely because of
the burden they place on social communication.
PD patients with dysarthria have demonstrated negative
self-perception, expressing frustration as they feel less
competent in their communication abilities and less able to
communicate what they intend to say [65]. Importantly, this
was found to be independent of actual intelligibility of
speech, highlighting that negative self-perceptions can arise
regardless of the severity of the communication problem
[65]. Communication in PD might also be affected by
cognitive changes. For example, one study identified that
many PD patients have to put conscious effort into speaking
[66]./is effort can be draining and can cause patients to feel
frustrated and embarrassed.
2.4. Prosody Identification Deficit. In addition to difficulty
producing expressive speech, PD patients also have difficulty
identifying the emotional prosody (i.e., pitch, intonation,
and rhythm used to convey emotion) of others’ speech
[17, 67, 68]. Similar to emotion recognition problems, these
difficulties have been demonstrated for specific negative
prosodic emotions, including fear, anger, and disgust [69],
and for global prosody perception [16, 70]. Yet, some studies
report no deficit at all [68, 71]. Some researchers suggest that
prosody reception deficits only occur in those with later-
stage PD accompanied by cognitive impairment [72].
Furthermore, little attention has been paid to the effect of
dopaminergic therapy on prosody recognition in PD. In one
study, early-stage PD patients demonstrated prosody
identification deficits, particularly while ON medication
[73]. Another study found no difference in prosody rec-
ognition across medication states for both orally medicated
PD patients and those who had undergone deep brain
stimulation surgery [74]. However, it is clear that meth-
odological differences and sample variability might con-
tribute to the discrepant findings in this area.
2.5. Future Directions. /e aforementioned verbal and
nonverbal behaviors are vital components of communica-
tion that provide contextual information during social ex-
changes. /e loss of emotional expression and emotion
recognition abilities, as well as changes in emotional speech
production and reception, therefore, can have devastating
consequences for PD patients and their families. /ere is a
need for a more detailed study of facial and prosodic
emotion recognition deficits in this patient population.
While some of the discrepant findings might be due to
differences in methodology and sample characteristics,
others might be because of dopamine replacement therapy.
Futures studies are needed to provide clarification.
3. Negative Consequences Associated with
Social Symptoms of PD
3.1. Stigma. Stigma is a negative perception that discredits or
devalues an individual within a social or societal context
(e.g., people with disabilities and negatively stereotyped
racial groups); for an overview, see [75]. Some researchers
have argued that stigma exists because it provided an
evolutionary advantage via a disease-avoidance mechanism
[76, 77]. As Park and colleagues describe [77], this mech-
anism can operate in response to physical disability cues,
even when it is clear that the disability is not the result of a
contagious disease. In the present day, rather than pro-
moting group fitness, stigma has primarily negative effects
on those who experience it [78]. Moreover, self-stigma can
occur in individuals with chronic health conditions and can
further amplify the negative effects of public stigma (e.g.,
psychological distress and reduction of self-worth [79]).
Stigma can affect not only how patients are viewed and
treated by others around them but also how they view
themselves and their expectations about their future social
relationships.
Facial masking, in particular, has been researched as a
contributing factor to perceptions of stigma in PD. One
recent study found that stigma associated with facial
masking was the main reason for reduced quality of life in
PD patient participants [80]. In fact, stigma was found to be
a stronger mediator of the relationship between facial
masking and quality of life than depression. /is is, perhaps,
because observers tend to form negative impressions of
those with emotional expression deficits, which has been
shown in patients with facial paralysis [81]. /is can lead
patients to feel misunderstood and can hinder social
communication with caregivers and health care workers.
/e emotional expressions PD patients produce are often
mistaken by peers for negative emotions, which results in PD
Parkinson’s Disease 3
patients being considered less socially desirable, friendly,
and attentive [82–84]. As a result, PD patients are less able to
make a favourable first impression on peers, particularly
during emotional exchanges [85]. /is effect tends to be
worse for women with PD, perhaps due to social gender
norms that suggest women are more emotional [86]. Indeed,
Ma et al. [80] found that women tended to experience a
greater degree of perceived stigma as a result of facial
masking.
Similarly, PD patients with dysarthria have expressed
that they experience stigma when communicating in public
and worry about the perceptions of others. Listeners of
speech recordings rate PD participants as being more un-
happy and less friendly than their control counterparts [87].
/is is likely due to prosodic loss, as one study indicated that
listeners were less able to detect intended emotions such as
anger and disgust within PD patient speech recordings
compared to that of healthy controls [15]. Unfortunately, the
stigma associated with speech problems in PD can also make
patients vulnerable to discrimination. One study cited in-
cidences such as being asked not to read aloud in a Bible
study group as an example of the negative consequences
associated with speech-related stigma [66]. It is, therefore,
not surprising that nearly 40% of patients report that
communication changes in PD are among their top disease-
related concerns [88].
Stigma accompanies many mental and physical disor-
ders, but in the case of PD, it can be particularly detrimental.
Perception of stigma is directly related to perceived quality
of life for PD patients, even when controlling for disease
severity and motor difficulties [89]. As the disease prog-
resses, patients with PDmight experience an exacerbation of
nonmotor symptoms, in addition to motor symptoms,
leading to stigma associated with their communication
problems (for review, see [90]). /e stigma associated with
both nonmotor (communication) deficits and motor
symptoms puts these patients at a greater risk for dehu-
manization, a link that has been demonstrated in other
patient populations (e.g., those with mental illnesses) who
are perceived as lower in social status due to their disorder
[91].
3.2. Dehumanization. Dehumanization is categorized by a
denial of the capacity for experience (e.g., feelings of pleasure
or pain) and/or agency (e.g., making plans or choices) of
another person [92]. Dehumanization does not have to be
explicit and discriminatory, and it can also occur implicitly
based on automatic, unconscious perceptions of others [93].
Unfortunately, dehumanization is a common occurrence
in both formal (i.e., with physicians or in a healthcare
setting) and informal (i.e., with friends or loved ones) health
contexts [94], taking forms such as neglecting patient per-
spectives or ignoring patients concerns. Although it can have
negative effects on patients, dehumanization by healthcare
workers might offer these workers some protection from the
symptoms of burnout [95]. Patient-centered care ap-
proaches have made some headway in combating dehu-
manization by physicians and healthcare workers; however,
more work is needed to overcome dehumanization in in-
formal health-related settings (i.e., by caregivers or even self-
dehumanization).
Dehumanization of PD patients in clinical settings can
occur for several reasons. Modern healthcare settings require
neurologists to assess and discuss all of the different aspects
of PD, including motor, cognitive, and social symptoms,
during appointments that typically last 30 to 60 minutes at
most. To extract important information from patients in a
very short amount of time, clinicians often rely on nonverbal
communication as a way of assessing how the patient is
doing overall [96]. Unfortunately, this strategy is likely to be
ineffective with PD patients who experience significant
socioemotional or communication deficits. Due to facial
masking and dysarthria, it can take PD patients much longer
to communicate in social interactions [97], including those
with clinicians. In some instances, a caregiver (e.g., spouse
and child) will take control of an appointment to provide the
clinician with pertinent informationmore quickly. Although
effective at transmitting information, this approach can be
detrimental, as the patient might feel as though their voice
has not been heard.
Clinicians’ negative perceptions of PD patients as a result
of social communication challenges can also contribute to
dehumanization in healthcare settings. For example, clini-
cians tend to perceive PD patients with facial masking as
more depressed, less intelligent, and less sociable than pa-
tients without [98]. Healthcare workers with less experience
were particularly guilty of this, labelling PD patients with
masking as having a more negative personality [99]. Simi-
larly, clinicians have been found to judge patients with
acquired dysarthria as less cognitively competent than those
without communication challenges [100]. Awareness of the
tendency to dehumanize patients with facial masking and
dysarthria is an important first step towards mitigating this
issue.
3.3. Social Isolation and Loneliness. One major outcome of
stigma and dehumanization is social isolation, as insecurity
in social spaces and internalized stigma can lead PD patients
to avoid social interactions or avoid disclosing information
about themselves to others [101]. Repeated social isolation
can put one at risk for experiencing loneliness, which is a
persistent and debilitating state of perceived social discon-
nection that can affect mental and physical health. Impor-
tantly, feelings of loneliness are distinct from objective
assessments of social isolation, although both can negatively
affect health outcomes [102]. Cacioppo et al. [103] identified
loneliness, in particular, as a risk factor for morbidity and
mortality. Moreover, there are clear health-related and
cognitive benefits to being well connected to a diverse social
network [104].
Unfortunately, rates of loneliness and associated psy-
chological distress can increase with age among older adults
[105]. Compared to young and middle-aged adults, older
adults typically experience decreasing physiological resil-
ience, and loneliness can further exacerbate their suscepti-
bility to the adverse effects of life stressors [106]. Social
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isolation and loneliness are critical factors to address in older
adults in general, and PD patients and caregivers are faced
with additional disease-related challenges that might make
them more prone to experiencing these issues.
/e social symptoms of PD often directly lead to feelings
of loneliness and social isolation. Indeed, one study found
that patients with greater facial masking have reported
experiencing greater self-reported social exclusion [21]. In
another study, over half of PD participants blamed masking
specifically for their feelings of social distance between
themselves and their partners [107]. Dysarthria can con-
tribute to social withdrawal as well. Feelings of frustration
and embarrassment caused by speech difficulties in PD can
lead patients to avoid communication opportunities
[108, 109]. Moreover, even when PD patients with dysarthria
do attempt to communicate, conversation partners tend to
dominate [110].
Unfortunately, as patients begin to experience greater
feelings of loneliness, they might also experience changes in
the healthcare they receive. In one study, clinicians who
interacted with elderly patients self-declared that they and
their colleagues provided more comprehensive care to the
patients who seemed less lonely and who had greater social
support [103]. /is suggests that experiencing social
symptoms in PD can initiate a positive feedback loop in
which the negative consequences (e.g., stigma and dehu-
manization) of these symptoms lead to social withdrawal,
which further exacerbates the negative consequences.
/e caregivers of PD patients are also at risk for expe-
riencing loneliness and social isolation. Caregiving can be
stressful, and across several conditions (e.g., depression,
autism, or multiple sclerosis), caregivers are at a greater risk
for depression, feelings of general fatigue, and decreases in
life satisfaction [111, 112]. For caregivers of PD, those with
low self-efficacy in their caregiving abilities are more likely to
experience loneliness [113]. However, this can be mitigated
by greater social support through daily interactions or
support groups [113].
Overall, loneliness might manifest in patients with PD
due to the psychosocial and physical consequences that
accompany its progression (i.e., decreased emotional ex-
pression and physical autonomy). Likewise, caregivers might
also experience feelings of loneliness as their caregiving role
can limit their ability to maintain engagement with others
outside of this role. Fortunately, although loneliness is a
multifaceted issue, loneliness is cognitive in nature, and
some researchers have suggested that clinicians can inter-
vene by helping patients develop a more positive outlook on
the disease and their achievements and challenges [114].
4. Clinical Implications
Early identification of socioemotional symptoms is essential
for preventing subsequent negative consequences. As one
study mentions, delayed intervention can lead to the de-
velopment of negative coping strategies such as withdrawal
and denial [64]. Furthermore, it has been well established
that certain symptoms of PD manifest years before the
disease is ever diagnosed [115, 116]. Clinicians who are
aware of these sometimes “invisible” socioemotional
symptoms can incorporate their management into a holistic
treatment plan.
/ere are several tools which can be used to assess the
severity of PD-related social symptoms, as well as their
related consequences. For example, the Dysarthria Impact
Profile (DIP) is a self-assessment tool which evaluates the
psychosocial impact of acquired dysarthria [117] and has
demonstrated reliability and validity in PD patient samples
[118–120]. /e 39-Item Parkinson’s Disease Questionnaire
(39-PDQ [121]) is considered the most well-validated in-
strument for assessing health-related quality of life in PD by
the Movement Disorder Society [122]. It includes items that
address communication difficulties, social isolation and
loneliness, stigma, and social support and, thus, could be
used as an effective measure to assess and monitor PD-
related social symptoms and associated negative
consequences.
Furthermore, education for patients and their caregivers
about socioemotional symptoms and associated conse-
quences can help prepare patients for these potential issues
[107]. Moreover, encouraging patients to have an active role
in educating their family and friends about their disease can
be helpful in reducing social isolation [64, 114].
4.1. Management of Social Symptoms in PD. Some PD pa-
tients have employed informal strategies to compensate for
socioemotional symptoms such as facial masking and dys-
arthria. For example, patients might turn to other channels
of communication (e.g., physical touch, e-mail, and note
writing) to more clearly express their emotions [64, 107].
More formal strategies include exercises designed to pre-
serve or amplify patients’ communication abilities [107]. For
example, the Lee Silverman Voice Treatment (LSVT LOUD
[123]) combines vocal and respiratory exercises designed to
increase vocal loudness. LSVT LOUD has been shown to
improve both dysarthria and facial masking in PD patients
[124, 125] and was determined to be one of the most effective
treatments for improving pitch in a recent meta-analysis
[126]. However, it is essential to tailor treatment recom-
mendations to individual patient needs, especially in light of
the fact that certain treatments for emotional and com-
munication symptoms might not be viewed positively by
patients. For example, one group of patients indicated that
speech drills were not sufficient to address important social
aspects of communication [66]. Choral singing treatment
appears to be more enjoyable for patients [127] and yields
some positive outcomes, such as improvements in mood
[128], perhaps due to its highly social nature.
Importantly, it is currently unclear how dopaminergic
medication affects social symptoms such as facial masking,
dysarthria, and the perception of verbal and nonverbal
emotional expression. Despite the lack of evidence in this
area, some patients report self-administering extra dopa-
minergic medication to help alleviate social symptoms such
as facial masking [107]. However, this could cause further
problems (e.g., dyskinesias) in the long run [129]. As pre-
viously mentioned, dopaminergic medication can also have
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differential effects on the cognitive symptoms of PD, im-
proving some, despite worsening others, and it is possible
that the same effect could be observed for social symptoms.
Further research must be conducted to investigate whether
and how the social symptoms of PD are affected by con-
ventional dopaminergic treatments.
5. Conclusions
In conclusion, there is ample evidence that PD involves social
consequences, and that the hallmark motor symptoms of PD
might further contribute to these issues. Specifically, motor
deficits including bradykinesia of the facial muscles and dys-
arthria can affect patients’ ability to express emotions or impact
speech during conversations, respectively. /e emergence of
social symptoms is common and disruptive to patients’ lives, as
feelings of stigma, dehumanization, and loneliness might lead
patients to withdraw from social situations. Even further, these
social symptoms might extend to caregivers of patients with
PD, as they might also feel lonely due to the nature of their
caregiver role and the consequences of stigmatization. In the
future, systematic review of topics related to the social
symptoms of PD would help to extend and clarify the findings
presented in this narrative review.
Unfortunately, the social symptoms of PD are less well
recognized and can significantly decrease patients’ quality of
life. /ese socioemotional symptoms and consequences of
PD are addressable but anticipating potential social issues
requires (a) acknowledging and preparing for them before
they occur and (b) actively re-examining whether social
needs are being adequately met throughout the course of the
disease. Fortunately, recent research proposes novel strat-
egies to help address these issues.
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